7011:TSE
Mitsubishi Heavy Industries, Ltd.
Data as of 2026-03-09 - not real-time
¥4,580.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Mitsubishi Heavy Industries is trading at ¥4,580, comfortably above its 20‑day SMA of ¥4,895 and 50‑day SMA of ¥4,595, but still below the 200‑day SMA of ¥3,975, indicating a short‑term bullish tilt within a longer‑term uptrend. The RSI sits at 44, suggesting neutral momentum, while the MACD histogram is negative and the signal line is bearish, hinting at possible near‑term downside pressure toward the support level of ¥4,375. Valuation metrics are starkly misaligned: a trailing P/E of 56.5× dwarfs the industry average of 29.5× and the DCF‑derived fair value of ¥2,229 is less than half the current price, flagging significant overvaluation. Dividend sustainability appears solid with a 0.52% yield, a payout ratio under 30%, and ample operating cash flow, though the modest yield offers limited income appeal. Recent material news points to strategic moves into private low‑Earth‑orbit infrastructure and advanced hydrogen‑based power generation, which could diversify earnings and support future growth. However, revenue contraction of 2.9% and modest margins (gross 21%, operating 10%) temper enthusiasm, and the stock’s volatility of 42.8% plus a max drawdown of 28.5% underscore heightened price risk.
Overall, the stock sits in a sector characterized by cyclical industrial exposure and medium regulatory scrutiny, with a beta of 0.73 indicating moderate market sensitivity. The “Extreme Greed” sentiment on the fear‑greed index reflects bullish market bias, yet the technical and fundamental disconnect suggests caution. Investors should weigh the overvalued price against the company’s strategic initiatives and robust dividend profile before committing.
Overall, the stock sits in a sector characterized by cyclical industrial exposure and medium regulatory scrutiny, with a beta of 0.73 indicating moderate market sensitivity. The “Extreme Greed” sentiment on the fear‑greed index reflects bullish market bias, yet the technical and fundamental disconnect suggests caution. Investors should weigh the overvalued price against the company’s strategic initiatives and robust dividend profile before committing.
Trading Recommendations
Short Term
< 1 yearhold
Conviction: 6/10
Key Factors
- Bearish MACD histogram and proximity to support level
- Neutral RSI indicating no strong momentum
- High valuation metrics (P/E, DCF gap) limit upside
Medium Term
1–3 yearsbuy
Conviction: 7/10
Key Factors
- Strategic entry into space and hydrogen markets
- Stable dividend with low payout ratio
- Bullish SMA alignment suggesting continued uptrend
Long Term
> 3 yearshold
Conviction: 6/10
Key Factors
- Overvalued price relative to fundamentals
- Diversification into high‑growth sectors offsets earnings contraction
- Sustainable dividend provides defensive floor
Key Metrics & Analysis
Financial Health
Revenue Growth-2.90%
Profit Margin5.36%
P/E Ratio56.5
Debt/Equity34.74
P/B Ratio5.8
Op. Cash Flow¥803.0B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI43.9
Support¥4,375.00
Resistance¥5,208.00
MA 20¥4,895.10
MA 50¥4,595.06
MA 200¥3,974.51
MACDBearish
VolumeStable
Fear & Greed Index75.89
Valuation
Fair Value¥2,228.86
Target Price¥5,265.27
Upside/Downside14.96%
GradeOvervalued
TypeValue
Dividend Yield0.52%
Risk Assessment
Beta0.73
Volatility42.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.